Nomura Asset Management Co. Ltd. Purchases 2,506 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Nomura Asset Management Co. Ltd. boosted its position in Ascendis Pharma A/S (NASDAQ:ASND) by 13.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,506 shares of the biotechnology company’s stock after purchasing an additional 2,506 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Ascendis Pharma A/S were worth $2,823,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Groupama Asset Managment bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter worth approximately $60,000. Frazier Life Sciences Management L.P. purchased a new stake in Ascendis Pharma A/S during the 3rd quarter valued at about $19,908,000. Zimmer Partners LP bought a new stake in Ascendis Pharma A/S during the 3rd quarter valued at about $11,646,000. American Century Companies Inc. raised its holdings in Ascendis Pharma A/S by 17.5% in the fourth quarter. American Century Companies Inc. now owns 407,294 shares of the biotechnology company’s stock worth $56,072,000 after buying an additional 60,548 shares during the last quarter. Finally, Maven Securities LTD bought a new position in shares of Ascendis Pharma A/S in the third quarter worth approximately $7,466,000.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Cantor Fitzgerald raised their price target on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, February 25th. UBS Group started coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price target for the company. JPMorgan Chase & Co. increased their price objective on Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, March 18th. The Goldman Sachs Group lifted their price objective on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Finally, Morgan Stanley set a $180.00 target price on shares of Ascendis Pharma A/S in a research note on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Ascendis Pharma A/S has an average rating of “Moderate Buy” and an average target price of $204.64.

Ascendis Pharma A/S Price Performance

NASDAQ:ASND opened at $152.15 on Thursday. The firm has a market capitalization of $9.23 billion, a price-to-earnings ratio of -21.43 and a beta of 0.61. The business has a 50 day simple moving average of $145.65 and a 200-day simple moving average of $137.96. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.64. As a group, analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.